 |
Indication & Dosage |
| |
| |
| Oral |
| ADVANCED PROSTATE CANCER |
| Adult:
1 mg as a single daily dose by SC Inj. As depot preparations: 3.75 mg once a mth, as a single IM/SC Inj; or 11.25 mg every 3 mth via SC inj. Alternatively, an implant containing 72 mg of leuprorelin acetate may be inserted subcutaneously into the inner part of the upper arm; releasing drug at a controlled rate of 120 mcg/day for 12 mth. An anti-androgen such as cyproterone acetate may be given for a few days prior to starting treatment and continued for 3 wk, to prevent disease flare. |
| |
| Oral |
| ENDOMETRIOSIS AND UTERINE FIBROIDS |
| Adult:
As depot preparations: 3.75 mg every mth given as a single IM/SC inj or 11.25 mg every 3 mth as IM depot Inj. Initiate treatment during the 1st 5 days of menstrual cycle up to 6 mth (for endometriosis) or 3 mth (for women with anaemia due to uterine fibroids). |
| |
| Oral |
| PRECOCIOUS PUBERTY |
| Child:
Initially, 50 mcg/kg daily by SC inj, may be titrated upwards by 10 mcg/kg/day if total suppression of ovarian or testicular steroidogenesis is not achieved. As depot preparations: ≤25 kg: 7.5 mg; >25-37.5 kg: 11.25 mg and >37.5 kg: 15 mg; doses to be given via IM/SC inj every 4 wk; may titrate dose upwards in increments of 3.75 mg every 4 wk if down-regulation is not achieved. |
| |
| Oral |
| AS PREPARATION FOR UTERINE SURGERY E.G. ENDOMETRIAL ABLATION OR RESECTION |
| Adult:
As depot preparations: 3.75 mg as a single inj via IM/SC given 5-6 wk before the procedure, or mthly for 3-4 mth prior to surgery for uterine fibroids. |
|
| |
|
| Precautions |
Worsening of signs and symptoms of prostatic cancer, osteoporosis (including drug induced). For management of central precocious puberty, treatment should be discontinued before the girl reaches 11 yr old or the boy reaches 12 yr old. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
ECG changes/ischaemia, oedema, insomnia/sleep disorders, pain, headache, dizziness, nervousness, paraesthesias, impotence/decreased libido, gynaecomastia/breast tenderness/changes, hot flushes/sweats, GI disturbances, anorexia, constipation, nausea/vomiting, myalgia, bone pain, urinary frequency/urgency/disorders, haematuria, dyspnoea, anaemia, dermatitis, acne/seborrhoea, asthenia, amenorrhoea, reduced bone density. |
| |
|
| Adverse Drug Reactions |
Thrombocytopenia and leucopenia. |
| |
|
|
|
